Status:

COMPLETED

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

Lead Sponsor:

Boehringer Ingelheim

Conditions:

COPD

Eligibility:

All Genders

40+ years

Brief Summary

The primary objective is to compare the effectiveness of maintenance therapy initiation with the combination treatment Tiotropium and Olodaterol (Olo+Tio) compared with LABA/ICS combination in COPD as...

Eligibility Criteria

Inclusion

  • At least one prescription for Tio+Olo combined inhaler or a LABA/ICS combined inhaler between 1 January 2013 and 31 March 2019.
  • The first dispensing of either Tio+Olo or LABA/ICS combined inhaler will be defined as the index date.
  • For the main analyses, only fixed dose combination (FDC) inhalers will be included. Sensitivity analyses will also accept free combinations of LABA/ICS.
  • At least one diagnosis of COPD at any time prior to the index date.
  • At least one year of continuous medical and pharmacy health plan eligibility prior to the index date will be required to allow a baseline period for the covariates and identification of new use of the study drugs.

Exclusion

  • To increase the likelihood of a true diagnosis of COPD, we will exclude:
  • All patients less than 40 years of age on the index date, and
  • All patients with a diagnosis of asthma in the year prior to the index date
  • To limit the population to those without severe lung compromise outside of COPD, we will exclude individuals with lung cancer, interstitial lung disease, or lung transplant identified at any time prior to the index date
  • To restrict the cohort to new users of Tio+Olo or LABA/ICS, we will exclude any individual with use of either Tio+Olo, LABA/ICS, or LABA/LAMA/ICS combination therapy in free or fixed form for at least one year prior to the index date.

Key Trial Info

Start Date :

November 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 4 2019

Estimated Enrollment :

42953 Patients enrolled

Trial Details

Trial ID

NCT04138758

Start Date

November 1 2019

End Date

November 4 2019

Last Update

November 15 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

HealthCore, Inc.

Watertown, Massachusetts, United States, 02472

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS | DecenTrialz